3Baggstrom M,Socinski MA,Hensing T,et al.Third generation chemotherapy regimens (3GR) improve survival over second generation regimens (2GR) in stage ⅢB/Ⅳ non-small cell lung cancer (NSCLC):a meta-analysis of the published literature.Proc Am Soc Clin Oncol,2002,21:306a. 被引量：1
5Delbaldo C.Adding a second or a third drug to a chemotherapy regimen in patients with advanced non-small cell lung carcinoma (NSCLC):a meta-analysis of the lietrature.Proc Am Soc Clin Oncol,2003,22:623. 被引量：1
6Baggstrom M,Socinski MA,Hensing T,et al.Addressing the optimal number of cytotoxic agents in stage ⅢB/Ⅳ non-small cell lung cancer (NSLCC):a meta-analysis of the published literature.Proc Am Soc Clin Oncol,2003,21:306. 被引量：1
7Tiseo M,Boni L,Ardizzoni A.Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer:does cisplatin versus carboplatin make a difference? J Clin Oncol,2005,23:6276-6277. 被引量：1
8Fossella F,Devore R,Kerr R,et al.Randomized phase Ⅲ trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing regimens.The TAX 320 Non-Small Cell Lung Cancer Study Group.J Clin Oncol,2000,18:2354-2360. 被引量：1
9Hanna N,Shepherd FA,Fossella FV,et al.Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with nonsmall-cell lung cancer previously treated with chemotherapy.J Clin Oncol,2004,22:1589-1597. 被引量：1
10Pfister DG,Johnson DH,Azzoli GG,et al.American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline:update 2003.J Clin Oncol,2004,22:330-353. 被引量：1
